Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 3/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5072191 | 0.83 | PTGER4 (0.31) | PTGER4 | |
| SCHEMBL5613040 | 0.81 | PTGER4 (0.35) | PTGER4L3MBTL1PIN1LTB4RLTB4R2 | |
| SCHEMBL5075349 | 0.72 | PTGER4 (0.52) | PTGER4L3MBTL1CES1NCEH1 | |
| SCHEMBL5605038 | 0.70 | — | — | |
| SCHEMBL7946127 | 0.66 | TSHR (0.30) | TSHR | |
| SCHEMBL6558651 | 0.65 | PTGER3 (0.61) | PTGER4 | |
| SCHEMBL6557846 | 0.64 | PTGER4 (0.55) | PTGER4 | |
| SCHEMBL5604828 | 0.64 | PTGER4 (0.43) | PTGER4PIN1FFAR2CYSLTR2CYSLTR1 | |
| SCHEMBL29424287 | 0.63 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL9986079 | 0.63 | L3MBTL1 (0.67) | PTGER4L3MBTL1CES1NCEH1LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7255984-B2 | Combination therapy for osteoporosis | PFIZER INC. (US) | 2007-08-14 | — | — | US | claimed |
| US-20010009920-A1 | Estrogen agonist/antagonist and a prostaglandin or a prostaglandin agonist/antagonist | KE HUA ZHU (US) | 2001-07-26 | — | — | US | claimed |
| EP-0883404-A1 | COMBINATION THERAPY FOR OSTEOPOROSIS | PFIZER INC. (US) | 1998-12-16 | — | — | EP | claimed |
| WO-1997031640-A1 | COMBINATION THERAPY FOR OSTEOPOROSIS | PFIZER INC. (US) | 1997-09-04 | — | — | WO | claimed |
| EP-1932543-A2 | Combination therapy for osteoporosis consisting of an estrogen agonist/antagonist and a growth hormone secretagogue | Pfizer, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| EP-1236475-A2 | Combination therapy for osteoporosis consisting of an estrogen agonist/antagonist and a growth hormone secretagogue | PFIZER INC. (US) | 2002-09-04 | — | — | EP | disclosed |
| US-6323232-B1 | TREATMENT OF OSTEOPOROSIS WITH LASOFOXIFENE AND PGE2 | PFIZER INC. | 2001-11-27 | — | — | US | disclosed |
| EP-0883404-A1 | COMBINATION THERAPY FOR OSTEOPOROSIS | PFIZER INC. (US) | 1998-12-16 | — | — | EP | disclosed |
| WO-1997031640-A1 | COMBINATION THERAPY FOR OSTEOPOROSIS | PFIZER INC. (US) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009920-A1 | Estrogen agonist/antagonist and a prostaglandin or a prostaglandin agonist/antagonist | PTGER1, PTGER2, PTGER4 | PTGER4 3/4885L3MBTL1 4604/4885PIN1 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.